Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy in the Management of Gleason Group 5 Prostate Cancer
Phase of Trial: Phase I/II
Latest Information Update: 26 Oct 2018
Price : $35 *
At a glance
- Drugs Nivolumab (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 28 Sep 2018 Status changed from not yet recruiting to recruiting.
- 14 Aug 2018 Planned initiation date changed from 1 Aug 2018 to 1 Nov 2018.
- 04 Jun 2018 New trial record